Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 634 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... August 22, 2024 Study Probes Awareness of Alcohol’s Link to Cancer January 18, 2023 Many Older Adults Screened Unnecessarily for Common Cancers August 27, 2020 In memory of Dame Deborah James June 29, 2022 Load more HOT NEWS Can Cancer Prevention Be Better Integrated into Primary Care? From smart knives to virtual reality tumours: five innovations in understanding... How to Maintain Your Sexual Health During and After Lung Cancer COVID-19, Cancer, and Uncertainty: An Oncologist’s Perspective on Coping
